The FDA has granted Orphan Drug Designation to NS-229, a selective JAK1 inhibitor being developed by NS Pharma for eosinophilic granulomatosis with polyangiitis (EGPA).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.